Group Art Unit: unknown

Examiner: unknown

#

PATENT / DOCKET NO. 12964.17 Customer No. 000027683

1

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:
Hassan Jomaa

Serial No.: 09/673,389

Filed: October 13, 2000

For: PROCESS FOR IDENTIFYING
CHEMICAL ACTIVE INGREDIENTS
AND ACTIVE INGREDIENTS FOR
INHIBITING THE
1-DESOXY-D-XYLULOSE-5-PHOSPHATE
BIOSYNTHESIS PATHWAY

RESPONSE AND TRANSMITTAL OF NOTIFICATION OF MISSING REQUIREMENTS

Commissioner of Patents **Box: PCT (DO/EO/US)** Washington, D. C. 20231

Dear Sir:

In response to the Notification of Missing Requirements under 37 U.S.C. 371 in U.S. Designated/Elected Office and response to Notification to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures dated September 5, 2001, regarding the above-identified application, Applicant submits the following:

- 1. Original and copy of this Transmittal;
- 2. Copy of the Notification of Missing Requirements;
- 3. Copy of the Notification to Comply with Requirements;
- 4. Paper copy of the "Sequence Listing" previously submitted on October 13, 2000 with the initial filing;
- 5. Statement for Submission of Sequence Listing;
- 6. Computer Readable form (CRF) of the "Sequence Listing"; and
- 7. Return postcard.

PATENT / DOCKET NO. 12964.17 Customer No. 000027683

The Commissioner is hereby authorized to charge any further fees associated with this communication or to credit any overpayment to Deposit Account No. 08-1394.

Respectfully submitted,

Brian J. Hubbard Reg. No. 45,873

Date: Nov. 5, 2001 HAYNES AND BOONE, LLP 901 Main Street - Suite 3100 Dallas, Texas 75202-3789 Phone: 214/651-5058

Fax: 214/651-5940 File: 12964.17

D.956017.1

I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Box: PCT (DO/EO/US), Commissioner for Patents, Washington, D.C. 20231 on

tuhur

				ates Patent and Trader Washington.	
U.S. APPLICATION NO.		FIRST NAMED APPLICA	NT	ATTY. DOCKET NO.	
09/673389		HASSAN	J	12964.17	
			INTERNA	ATIONAL APPLICATION NO.	
WARREN B KICE HAYNES AND BOONE		•	PC	CT/EP99/02463	
3100 BANK OF AMERICA	A PLAZA		I.A. FILING D	DATE PRIORITY DATE	
901 MAIN STREET			L		
DALLAS, TX 75202 3789			13 APR		
			DATE MA	um 05 SEA	2001
NOTIFICATION OF STA		UIREMENTS UN TED/ELECTED O		71 IN THE UNITE	D .
1. The following items have					
		1.494) 🔁 an Elected):	
U.S. Basic Nation		Indication of Sma			
<u> </u>	national application.		international applicati		
	on of inventors(s).		ticle 19 amendments in	nto English.	,
Copy of Article 1		Other:			
Priority Documen		ion Donast in Factish .			
		ion Report in English a nal Preliminary Examir			
2. Applicant has requested	early processing unde	r 35 [] S C 371(f) but	has not filed the follow	ving indicated items and/o	
he indicated items in paragrap	oh 3 below. The Basic	National Fee and the c	onv of the internations	ving indicated items and/o	1. 1
prior to 20 or 30 months from	the priority date to av	oid abandonment.	opy of the international	a apprication must be med	•
U.S. Basic Nation	nal Fee.	Copy of the intern	national application.		
3. The following items MUS	F be furnished within t	he period set forth belo	w in order to complete	the requirements for	
		glish. A processing fee	will be required if sul	bmitted	
later than the	e appropriate 20 or 30	months from the priori	ty date.		. 2
The current	translation is defective	for the reasons indicate	ed on the attached Noti	ice of Defective	
Translation.	6				
<u> </u>		lation of the application		ater than the	
		the priority date (37 CF in compliance with 37 C		neonerly identifying	
		nternational application			
surcharge wi	ill be required if submi	tted later than the appro	opriate 20 or 30 month	s from the priority	
		s not comply with 37 C	CFR 1.497(a) and (b) fe	or the reasons	
	the attached PCT/DO	'EO/917. eclaration later than the	annenneiste 20 oe 20 i	months from the	
	(37 CFR 1.492(e)).	centration rater than the	appropriate 20 of 30 i		
. Additional claim fees of \$_		large entity 🦳 small er	itity, including any req	quired multiple dependent	
laim fee, are required. Appli	cant must submit the a	dditional claim fees or	cancel the additional cl	laims for which fees are	
ue (37 CFR 1.492(g)). See at	ttached PTO-875.				
Applicant has not submit	tted the required seque	nce listing pursuant to 3	37 CFR 1.821-1.825.	See attached	
CI/DO/EO/920.	. ,		•		
ALL OF THE ITEMS SET F MONTHS FROM THE DAT THE PRIORITY DATE FOR	E OF THIS NOTICE THE APPLICATIO	OR BY 22 OR 32 MO N, WHICHEVER IS	ONTHS (where 37 CF	R 1.495 applies) FROM	
THE SPOND WILL RESULT IN THE METERS IN THE SECOND WILL RESULT WILL RESULT IN THE SECOND WILL RESULT WILL RESULT WILL RESULT WILL RESULT WILL WILL WI		•	tension of time under	the provisions of 37 CFR	
If box 3a or 3c is checked, mnexes will be cancelled. A particle 19 amendment 30 (37 CFR 1.495(d)) month	processing fee will be a nts are cancelled since	required if submitted la a translation was not p	ter than 20 or 30 month	hs from the priority date.	
applicant is reminded that any ddress given in the heading an				ust be mailed to the	
		IUST be returne		onse.	
nclosed: . PCT/DO/EO/91		e of Defective Translat	ion		
☐ PTO-875	₹ PCT/	DO/EO/920 Pau	lette Kidwell, Para	ilegal	
ORM PCT/DO/EO/905 /Man	ch 2001)		nette Ridwell, Para		

Commissioner for Patents, Box PCT States Patent and Trademark Office Washington, D.C. 20231 www.uspto.gov

			www.uspto.gov	
U.S. APPLICATION NO.	FIRST NAMED APPLICANT		ATTY. DOCKET NO.	
09/673389	HASSAN	J	12964.17	
		INTERNATIONAL	L APPLICATION NO.	
WARREN B KICE HAYNES AND BOONE 3100 BANK OF AMERICA PLAZA 901 MAIN STREET		PCT/EP99/02463		
		LA. FILING DATE	PRIORITY DATE	
DALLAS, TX 75202 3789	•	13 APR 99	14 APR 98	
1		DATE MAILED:	05 SEP 200	

NOTIFICATION TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES

Applicant has submitted papers under 35 U.S.C. 371 to enter the national stage in the United States of America. The items indicated below, however, are missing. The period within which to correct the deficiency noted below and avoid abandonment is set forth in the accompanying Notification.

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

The application fails to comply with the requirements of 37 CFR 1.821-1.825.
This application does not contain, a "Sequence Listing" as a separate part of the
disclosure on paper copy or compact disc, as required by 37 CFR 1.821(c).
A copy of the "Sequence Listing" in computer readable format has not been submitted as
required by 37 CFR 1.821(e).
A copy of the "Sequence Listing" in computer readable form has been submitted. The
content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
The computer readable form that has been filed with this application has been found to be
damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A substitute computer readable form must be submitted as required by 37 CFR 1.825(d).
The paper copy or compact disc of the "Sequence Listing" is not the same as the
computer readable form of the "Sequence Listing" as required by 37 CFR 1.821(e).
Other:
A DDI ICANT MUCT DDOMDE
APPLICANT MUST PROVIDE:
An initial or substitute computer readable form (CRF) of the "Sequence Listing."
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL:
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation,
An initial or substitute computer readable form (CRF) of the "Sequence Listing." An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification. A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d). FOR QUESTIONS REGARDING COMPLIANCE WITH THESE REQUIREMENTS, PLEASE CALL: (703) 308-4216, for Rules interpretation, (703) 308-4212, for CRF submission help,

Paulette Kidwell, Paralegal

Telephone: 703-305-3656

Pil-2: 32

JC10 Rec'd PCT/PTO 0 3 JAN 2002 69/673,389

> HAYNES AND BOONE, LIP Attorneys 901 Main Street Stair 3100+ Dallas, Texas 75202-3789

USPTO MAIL CENTER

Commissioner for Patents **Box: PCT (DO/EO/US)**Washington, D.C. 20231